Atrial Fibrillation and Cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorHAJJAR, Ludhmila Abrahao
dc.contributor.authorFONSECA, Silvia Moulin Ribeiro
dc.contributor.authorMACHADO, Theuran Inahja Vicente
dc.date.accessioned2022-04-19T12:57:03Z
dc.date.available2022-04-19T12:57:03Z
dc.date.issued2021
dc.description.abstractCancer patients have a higher risk of atrial fibrillation (AF) than general population, the pathophysiology mechanisms involves the pro inflammatory status of immune system in these patients and the exacerbated inflammatory response to cancer treatment and surgeries. Adequate management and prophylaxis for its occurrence are important and reduce morbidity and mortality in this population. There is a challenge in AF related to cancer to predict thromboembolic and bleeding risk in these patients, once standard stroke and hemorrhagic prediction scores are not validated for them. It is used CHA2DS2-VASc and HAS-BLED scores, the same as used in general population. In this review, we demonstrate correlated mechanisms to occurrence AF in cancer patients as well as therapeutic challenges in this population.eng
dc.description.indexPubMedeng
dc.identifier.citationFRONTIERS IN CARDIOVASCULAR MEDICINE, v.8, article ID 590768, 5p, 2021
dc.identifier.doi10.3389/fcvm.2021.590768
dc.identifier.issn2297-055X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/45897
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SAeng
dc.relation.ispartofFrontiers in Cardiovascular Medicine
dc.rightsopenAccesseng
dc.rights.holderCopyright FRONTIERS MEDIA SAeng
dc.subjectatrial fibrillationeng
dc.subjectcancereng
dc.subjectanticoagulationeng
dc.subjectcardiotoxicityeng
dc.subjectdrug-drug interactioneng
dc.subject.otheranticoagulationeng
dc.subject.othertherapyeng
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.titleAtrial Fibrillation and Cancereng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus12
hcfmusp.contributor.author-fmusphcLUDHMILA ABRAHAO HAJJAR
hcfmusp.contributor.author-fmusphcSILVIA MOULIN RIBEIRO FONSECA
hcfmusp.contributor.author-fmusphcTHEURAN INAHJA VICENTE MACHADO
hcfmusp.description.articlenumber590768
hcfmusp.description.volume8
hcfmusp.origemWOS
hcfmusp.origem.pubmed34336939
hcfmusp.origem.scopus2-s2.0-85127037628
hcfmusp.origem.wosWOS:000753658000001
hcfmusp.publisher.cityLAUSANNEeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAlexandre J, 2018, PHARMACOL THERAPEUT, V189, P89, DOI 10.1016/j.pharmthera.2018.04.009eng
hcfmusp.relation.referenceCannon CP, 2017, NEW ENGL J MED, V377, P1513, DOI 10.1056/NEJMoa1708454eng
hcfmusp.relation.referenceCheng WL, 2016, INT J CARDIOL, V219, P186, DOI 10.1016/j.ijcard.2016.06.009eng
hcfmusp.relation.referenceChu G, 2019, BLOOD REV, V35, P59, DOI 10.1016/j.blre.2019.03.005eng
hcfmusp.relation.referenceFarmakis D, 2014, J AM COLL CARDIOL, V63, P945, DOI 10.1016/j.jacc.2013.11.026eng
hcfmusp.relation.referenceFitzpatrick T, 2017, THROMB RES, V155, P101, DOI 10.1016/j.thromres.2017.05.006eng
hcfmusp.relation.referenceGibson CM, 2016, NEW ENGL J MED, V375, P2423, DOI 10.1056/NEJMoa1611594eng
hcfmusp.relation.referenceGoriacko P, 2018, EUR J HAEMATOL, V100, P488, DOI 10.1111/ejh.13045eng
hcfmusp.relation.referenceLopes RD, 2019, NEW ENGL J MED, V380, P1509, DOI 10.1056/NEJMoa1817083eng
hcfmusp.relation.referenceLopez-Fernandez T, 2019, REV ESP CARDIOL, V72, P749, DOI 10.1016/j.rec.2019.03.019eng
hcfmusp.relation.referenceMelloni C, 2017, EUR HEART J, V3, P192, DOI 10.1093/ehjqcco/qcx004eng
hcfmusp.relation.referenceMery B, 2017, INT J CARDIOL, V240, P196, DOI 10.1016/j.ijcard.2017.03.132eng
hcfmusp.relation.referenceMosarla RC, 2019, J AM COLL CARDIOL, V73, P1336, DOI 10.1016/j.jacc.2019.01.017eng
hcfmusp.relation.referenceQamar A, 2018, J AM COLL CARDIOL, V71, P2162, DOI 10.1016/j.jacc.2018.03.023eng
hcfmusp.relation.referenceVedovati MC, 2018, INT J CARDIOL, V269, P152, DOI 10.1016/j.ijcard.2018.07.138eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationfab78e0a-1e3b-4f8d-884d-227c020a86d0
relation.isAuthorOfPublication0d015ea0-4ad8-4002-bf31-306a6134b756
relation.isAuthorOfPublication78e4cf5e-3333-4f55-bad4-7a06e0cc61cd
relation.isAuthorOfPublication.latestForDiscoveryfab78e0a-1e3b-4f8d-884d-227c020a86d0
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_HAJJAR_Atrial_Fibrillation_and_Cancer_2021.PDF
Tamanho:
800.81 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/08
Artigos e Materiais de Revistas Científicas - ODS/03